Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode

Aim: To analyze the clinical, neurocognitive, and functional impact of prolactin levels according to sex in patients with a First Episode Psychosis (FEP). Methods: We measured prolactin levels in 221 non-affective FEP patients treated with antipsychotics (AP) and 224 healthy controls, at baseline an...

Descripción completa

Detalles Bibliográficos
Autores: Jordà-Baleri, Teresa, Garriga, Marina, Mezquida, Gisela, Cuesta, Manuel J., Martínez-Aran, Anabel, García-Rizo, Clemente, Lobo, Antonio, González Pinto, Ana, Díaz-Caneja, Covadonga M., Roldán, Alexandra, Vieta, Eduard, Baeza, Inmaculada, Trabsa, Amira, Montalvo, Itziar, Tortorella, Alfonso, Menculini, Giulia, Verdolini, Norma, Ramos-Quiroga, Josep Antoni, Sánchez Torres, Ana María, Bernardo, Miguel, Amoretti, Silvia, PEPs Group
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2024
País:España
Institución:Universidad Pública de Navarra
Repositorio:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
OAI Identifier:oai:academica-e.unavarra.es:2454/52406
Acceso en línea:https://hdl.handle.net/2454/52406
Access Level:acceso abierto
Palabra clave:First-episode psychosis
Functioning
Negative symptoms
Prolactin
Descripción
Sumario:Aim: To analyze the clinical, neurocognitive, and functional impact of prolactin levels according to sex in patients with a First Episode Psychosis (FEP). Methods: We measured prolactin levels in 221 non-affective FEP patients treated with antipsychotics (AP) and 224 healthy controls, at baseline and 2-year follow-up. We examined whether the relationships between clinical and functional variables were mediated by prolactin, controlling for antipsychotic use, according to sex. Results: Prolactin levels were higher in patients when compared to controls at both time points. Baseline factors associated with prolactin were chlorpromazine equivalents, attention, and executive functioning. In the FEP group, prolactin levels were associated with functioning and diminished expression in males, and with working memory in females. Prolactin levels (p=0.0134) played a role as a mediator between negative symptomatology (p=0.086) and functional outcome (p=0.008) only in FEP male patients at baseline. Conclusions: Prolactin plays a role in the functionality and clinical symptomatology of FEP patients. Our results suggest that pharmacological counselling in patients with hyperprolactinemia at baseline and negative symptomatology might improve their functional and clinical outcomes.

Similares en LA Referencia